Xofigo® (radium Ra 223 Dichloride) - Increased Incidence Of Fractures And Trend For Increased Deaths With Xofigo Used In Combination With Abiraterone And Prednisone/prednisolone

XOFIGO Recall Summary XOFIGO (radium Ra 223 dichloride), a cancer medication, is being recalled in Canada because studies show increased fracture rates and a trend toward higher death rates when used together with abiraterone and prednisone/prednisolone. The recall affects XOFIGO distributed across Canada. Patients currently taking this drug combination should contact their healthcare provider.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2018-11-08

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/3f4c6a14-94c1-4f46-a8d7-52c7f10a8ac5